|
|
|
|
In depth: Pharmaceuticals
The game changer - The pharmaceutical industry is facing uncertain times as a once-lucrative business model buckles under a globalising world economy.Charlotte Edmond reports on the companies and lawyers battling to secure all-important intellectual property...
|
|
|
Novartis Receives EU Approval For Menveo
The European Commission (EC) has granted a marketing authorization for Novartis' Menveo (Meningococcal group A, C, W135 and Y conjugate vaccine) in all 27 European member states.Menveo is indicated for the active immunization of adolescents (from 11...
|
|
|
Rabies could return to Britain if rules are relaxed, warn vets
Current rules stipulate a mandatory seven month delay between vaccination against rabies and being allowed to bring an animal into the UK with a European pet passport.But the EC wishes to harmonise the regulations for all pets travelling between member...
|
|
|
NeurogesX Reports Fourth Quarter and Year-End 2009 Results
SAN MATEO, Calif., March 18 /PRNewswire-FirstCall/ -- 2009 Corporate Highlights: Received U.S.Food and Drug Administration (FDA) approval of Qutenza (capsaicin) 8% patch for management of neuropathic pain associated with postherpetic neuralgia (PHN)Granted...
|
|
|
Novartis' conjugate vaccine Menveo gets European marketing nod
Novartis announced that the European Commission (EC) granted a Marketing Authorization for Menveo (Meningococcal Group A, C, W135 and Y conjugate vaccine) in all 27 European member states.Menveo is indicated for the active immunization of adolescents ...
|
|
|
EC Clears Novartis Quadrivalent Meningitis Vaccine
The European Commission granted pan-European clearance for Novartis' quadrivalent meningitis vaccine, Menveo (meningococcal group A, C, W135, and Y conjugate vaccine).The European decision comes less than a month after the vaccine was sanctioned by the FDA....
|
|
|
NeurogesX Reports Fourth Quarter and Year-End 2009 Results
Received U.S.Food and Drug Administration (FDA) approval of Qutenza long_space(capsaicin) 8% patch for management of neuropathic pain associated with postherpetic neuralgia (PHN) Granted European Commission (EC) approval of Qutenza for treatment of...
|
|
|
EU Approves Quadrivalent Conjugate Vaccine to Prevent Meningococcal Disease
-- The European Commission (EC) has approved a meningococcal (group A, C, W135 and Y) conjugate vaccine (Menveo) for the active immunisation of adolescents (from age 11) and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to...
|
|
|
Novartis receives EU approval for the first vaccine against meningitis
BASEL, Switzerland, March 18, (KUNA) -- The Swiss pharmaceutical company Novartis announced on Thursday that the European Commission (EC) granted a Marketing Authorization for the sale of Menveo, a vaccine against Meningococcal disease in all 27 European...
|
|
|
Novartis International AG (CH) - Novartis Receives Approval In The European Union For Menveo, First Quadrivale
* Meningococcal disease is a major cause of bacterial meningitis and sepsis with high consequent disability and mortality rates worldwide[1] * Dominant groups of meningococcal disease vary by country and region, and can change over time, making it an even more...
|
|
|
Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccin...
Profil Actualits Cotations Graphiques Agenda Publications Meningococcal disease is a major cause of bacterial meningitis and sepsis with high consequent disability and mortality rates worldwide[1] Dominant groups of meningococcal disease vary by country and...
|
|
|
Novartis International AG (CH) - Novartis Receives Approval In The European Union For Menveo, First Quadrivale
* Meningococcal disease is a major cause of bacterial meningitis and sepsis with high consequent disability and mortality rates worldwide[1] * Dominant groups of meningococcal disease vary by country and region, and can change over time, making it an even more...
|
|
|
Novartis Pharma Gets EU Approval For Menveo
Novartis Pharma has received European Commission (EC) approval for marketing authorisation of Menveo (Meningococcal Group A, C, W135 and Y conjugate vaccine) in all 27 European member states.Menveo is indicated for active immunization of adolescents ...
|
|
|
Novartis gets EC nod for Menveo quadrivalent conjugate vax
The European Commission has permitted Novartis to market Menveo (Meningococcal Group A, C, W135 and Y conjugate vaccine) in all 27 European member states.Menveo is indicated for the active immunization of adolescents and adults at risk of exposure to...
|
|
|
Novartis' meningococcal vaccine Menveo gets approval throughout EU
- Swiss drug maker Novartis (VTX:NOVN) announced today that the European Commission (EC) approved its meningococcal conjugate vaccine Menveo for marketing in all 27 EU states.According to Novartis, Menveo is indicated for the active immunization of...
|
|
|
Novartis receives approval in the European Union for Menveo(R), f...
Company: Novartis AG (NVS) Novartis International AG / Novartis receives approval in the European Union for Menveo(R), first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease processed and transmitted by Hugin AS.The issuer is...
|
|
|
Novartis receives approval in the European Union for Menveo(R), f...
Company: Novartis AG (NVS) Novartis International AG / Novartis receives approval in the European Union for Menveo(R), first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease processed and transmitted by Hugin AS.The issuer is...
|
|
|
Novartis receives approval in the European Union for Menveo(R), first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease
(Hugin via COMTEX) ----Novartis International AG / processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. * Meningococcal disease is a major cause of bacterial meningitis and sepsis with high consequent...
|
|
|
Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal ..
Novartis International AG / Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease processed and transmitted by Hugin AS.The issuer is solely responsible for the...
|
|
|
Novartis receives approval in the European Union for Menveo(R), first quadrivalent conjugate vaccine in the EU to help prevent m
Novartis International AG / eningococcal disease processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. * Meningococcal disease is a major cause of bacterial meningitis and sepsis with high consequent...
|
|
|
Medical device experts join PDS
Alan Taylor has notable expertise in CE Marking activities, microbiology and sterilisation, wound management, orthodontics, implantable devices and FDA audit requirements.He can advise on all aspects of medical device development. Brian Matthews has worked...
|
|
|
Angiogenesis: Research on angiogenesis described by scientists at Heart Research Institute
Today's Medical & Research News Angiogenesis Research on angiogenesis described by scientists at Heart Research Institute March 17th, 2010 Printer-Friendly Version City:Sydney Country:Australia Angiogenesis Cardiology Cardiovascular Drugs Experimental...
|
|
|
Commerzbank AG : Pre Stabilisation-Merck KGaA EUR 3.2bn 3 tranche
17th March 2010 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.Merck Financial Services GmbH EUR 500,000,000 2.125% Notes due 26 March 2012 - XS0497185271 EUR 1,350...
|
|
|
COMMERZBANK AG - Pre Stabilisation-Merck KGaA EUR 3.2bn 3 tranche
(PR Newswire Europe via COMTEX) ---- 17th March 2010 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.Merck Financial Services GmbH EUR 500,000,000 2.125% Notes due 26...
|
|
|
Pre Stabilisation-Merck KGaA EUR 3.2bn 3 tranche
17th March 2010 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.Merck Financial Services GmbH EUR 500,000,000 2.125% Notes due 26 March 2012 - XS0497185271 EUR 1,350...
|
